Trial Profile
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Adolescents and Children
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics; Registrational
- Sponsors Gilead Sciences
- 31 Jan 2023 Planned number of patients changed from 125 to 172.
- 31 Jan 2023 Status changed from active, no longer recruiting to recruiting.
- 20 Dec 2022 Planned End Date changed from 1 Jul 2026 to 1 Dec 2024.